Mark Purcell
Stock Analyst at Morgan Stanley
(1.03)
# 3,725
Out of 4,944 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $121.08 | -5.85% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $48.78 | +12.76% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $39.15 | +12.39% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $77.39 | +9.84% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $51.10 | +134.83% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $121.08
Upside: -5.85%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $48.78
Upside: +12.76%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $39.15
Upside: +12.39%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $77.39
Upside: +9.84%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $51.10
Upside: +134.83%